Watch Ticker

Pharvaris N.V. Ordinary Shares

Go to Pharvaris N.V. Ordinary Shares Website

$22.68

(%)
Live
Previous Close

$22.68

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$1.2 billion USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The com...

Community
  • 0 posts discussing
0

Watchers

0

Visitors

Recent News

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

Related tickers: PHVS.

Read Full Article

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations. Mr. Nassif joins Pharvaris with more than 30 years of experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal, and capital allocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies.

Related tickers: PHVS.

Read Full Article
Trending Tickers
LASE

XNAS

$2.07
(%)
PACW

XNAS

$7.54
(%)
SMFL

XNAS

$3.37
(%)
SQ

XNYS

$73.53
(%)
MLGO

XNAS

$0.00
(%)